Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) received notification from the European Patent Office (EPO) of its intention to grant the company’s patent application related to a method of using Biomoda’s proprietary porphyrin-based compound to detect cancer and pre-cancerous cells in body fluid and tissue samples.
With the EPO patent, we may be able to launch CyPath® as a screening tool in Europe and start collecting revenue from sales prior to FDA approval in the U.S.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.